Compile Data Set for Download or QSAR
Report error Found 18 Enz. Inhib. hit(s) with all data for entry = 3512
TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402285(US10011627, 1)
Affinity DataIC50: 0.580nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402292(US10011627, 8)
Affinity DataIC50: 1.21nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402293(US10011627, 9)
Affinity DataIC50: 1.49nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402291(US10011627, 7)
Affinity DataIC50: 1.82nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402290(US10011627, 6)
Affinity DataIC50: 2.59nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402286(US10011627, 2)
Affinity DataIC50: 3.67nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402289(US10011627, 5)
Affinity DataIC50: 4.30nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402286(US10011627, 2)
Affinity DataIC50: 15.7nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402293(US10011627, 9)
Affinity DataIC50: 16.6nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402291(US10011627, 7)
Affinity DataIC50: 17.2nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402287(US10011627, 3)
Affinity DataIC50: 19.8nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402288(US10011627, 4)
Affinity DataIC50: 89nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402290(US10011627, 6)
Affinity DataIC50: 99.9nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402288(US10011627, 4)
Affinity DataIC50: 132nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402289(US10011627, 5)
Affinity DataIC50: 301nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 1(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402292(US10011627, 8)
Affinity DataIC50: 583nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402285(US10011627, 1)
Affinity DataIC50: 953nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSodium/glucose cotransporter 2(Human)
Youngene Therapeutics

US Patent
LigandPNGBDBM402287(US10011627, 3)
Affinity DataIC50: 2.56E+3nMAssay Description:The following method was used to determine the inhibitory activity of the compounds of the present invention on SGLT1 and SGLT2. The experimental met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent